Literature DB >> 14526216

Assessment of the relative potency of emtricitabine and lamivudine.

Raymond F Schinazi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14526216     DOI： 10.1097/00126334-200310010-00017

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  9 in total

1.  Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.

Authors:  Rochelle P Walensky; Paul E Sax; Yoriko M Nakamura; Milton C Weinstein; Pamela P Pei; Kenneth A Freedberg; A David Paltiel; Bruce R Schackman
Journal:  Ann Intern Med       Date:  2013-01-15       Impact factor: 25.391

2.  Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics.

Authors:  Elodie Valade; Jean-Marc Tréluyer; François Dabis; Elise Arrivé; Emmanuelle Pannier; Sihem Benaboud; Floris Fauchet; Naïm Bouazza; Frantz Foissac; Saïk Urien; Déborah Hirt
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

Review 3.  Emtricitabine: a review of its use in the management of HIV infection.

Authors:  James E Frampton; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Emtricitabine: an antiretroviral agent for HIV infection.

Authors:  Lynne M Bang; Lesley J Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  Nucleoside and nucleotide reverse transcriptase inhibitors in children.

Authors:  Carlo Giaquinto; Osvalda Rampon; Martina Penazzato; Federica Fregonese; Anita De Rossi; Ruggiero D'Elia
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

6.  Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase.

Authors:  Joy Y Feng; Eisuke Murakami; Suzana M Zorca; Allison A Johnson; Kenneth A Johnson; Raymond F Schinazi; Phillip A Furman; Karen S Anderson
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

7.  Lack of effect of lamivudine on Ebola virus replication.

Authors:  Lisa E Hensley; Julie Dyall; Gene G Olinger; Peter B Jahrling
Journal:  Emerg Infect Dis       Date:  2015-03       Impact factor: 6.883

8.  Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus.

Authors:  Yu Cong; Julie Dyall; Brit J Hart; Lisa Evans DeWald; Joshua C Johnson; Elena Postnikova; Huanying Zhou; Robin Gross; Oscar Rojas; Isis Alexander; Nicole Josleyn; Tengfei Zhang; Julia Michelotti; Krisztina Janosko; Pamela J Glass; Mike Flint; Laura K McMullan; Christina F Spiropoulou; Tim Mierzwa; Rajarshi Guha; Paul Shinn; Sam Michael; Carleen Klumpp-Thomas; Crystal McKnight; Craig Thomas; Ann E Eakin; Kathleen G O'Loughlin; Carol E Green; Paul Catz; Jon C Mirsalis; Anna N Honko; Gene G Olinger; Richard S Bennett; Michael R Holbrook; Lisa E Hensley; Peter B Jahrling
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

Review 9.  Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials.

Authors:  Nathan Ford; Zara Shubber; Andrew Hill; Marco Vitoria; Meg Doherty; Edward J Mills; Andy Gray
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.